Pharmacodynamics and dosing of aminoglycosides (Q35623060)

9 August 2017

1 reference

title

Pharmacodynamics and dosing of aminoglycosides (English)

1 reference

9 August 2017

1 reference

John Turnidge

1

1 reference

9 August 2017

1 September 2003

1 reference

Infectious Disease Clinics of North America

9 August 2017

1 reference

9 August 2017

17

1 reference

9 August 2017

3

1 reference

9 August 2017

503-28, v

1 reference

Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Experience with a once-daily dosing program of aminoglycosides in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Pharmacokinetics of once-daily dosing of gentamicin in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

The pharmacodynamics of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Extended interval aminoglycoside dosing: from concept to clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

In vivo postantibiotic effect in a thigh infection in neutropenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside adaptive resistance: importance for effective dosage regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Selection of aminoglycoside-resistant variants of Pseudomonas aeruginosa in an in vivo model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Physiology and antibiotic susceptibility of Staphylococcus aureus small colony variants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily dosing of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A model for predicting nephrotoxicity in patients treated with aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycosides: nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Determinants of efficacy and toxicity of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily aminoglycoside therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily dosing decreases renal accumulation of gentamicin and netilmicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Empiric therapy for infections in patients with granulocytopenia. Continuous v interrupted infusion of tobramycin plus cefamandole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside nephrotoxicity: modeling, simulation, and control

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside nephrotoxicity: do time and frequency of administration matter?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Nephrotoxicity Associated with Combined Gentamicin – Amphotericin B Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside-induced hearing loss in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Vestibular and cochlear toxicity of aminoglycosides--a review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Antibiotic prophylaxis in vascular reconstructive surgery: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Genetic factors in aminoglycoside toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Single-dose daily gentamicin therapy in urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Single daily doses of tobramycin in therapy of urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Single or multiple daily doses of aminoglycosides: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycosides: single or multiple daily dosing? A meta-analysis on efficacy and safety.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

What is the evidence for once-daily aminoglycoside therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside Administration as a Single Daily Dose : An Improvement to Current Practice or a Repeat of Previous Errors?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Single daily dose of aminoglycosides--a concept whose time has not yet come

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia i

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once versus twice daily amikacin in neonates: prospective study on toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Gentamicin and clindamycin therapy in postpartum endometritis: the efficacy of daily dosing versus dosing every 8 hours

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A randomized, prospective study comparing once-daily gentamicin versus thrice-daily gentamicin in the treatment of puerperal infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A prospective, randomized, double-blind studyof single high dose versus multiple standard dose gentamicin both in combination withmetronidazole for colorectal surgicalprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycoside dosing weight correction factors for patients of various body sizes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Safety of the bolus administration of gentamicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Serum levels of gentamicin and tobramycin after slow intravenous bolus injection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Safety of intravenous bolus administration of gentamicin in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Nonparametric meta-analysis of published data on kidney-function dependence of pharmacokinetic parameters for the aminoglycoside netilmicin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Predicting glomerular function from adjusted serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Use of Serum Creatinine Concentrations to Determine Renal Function1

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily aminoglycoside administration: new strategies for an old drug

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once daily gentamicin dosing in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily gentamicin dosing in newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Evaluation of gentamicin pharmacokinetics and dosing protocols in 195 neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Comparison of two gentamicin dosing schedules in very low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

An extended interval dosing method for gentamicin in neonates

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once- versus twice-daily gentamicin dosing in neonates >/=34 Weeks' gestation: cost-effectiveness analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Newborns and gentamicin--how much and how often?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Gentamicin serum concentrations in neonates born to gentamicin-treated mothers

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Role of aminoglycosides in the treatment of bacterial endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycosides in cystic fibrosis: a descriptive study of current practice in Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Once-daily aminoglycosides in the treatment of gram-positive endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Population analysis of once-daily dosing of gentamicin in patients with neutropenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Increased dosage requirements of gentamicin in burn patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Initial dosage regimens of gentamicin in patients with burns

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Gentamicin therapy in renal failure: a nomogram for dosage.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Gentamicin serum concentrations: pharmacokinetic predictions

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Pharmacokinetic dosing of aminoglycosides: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Evaluation of four once-daily aminoglycoside dosing nomograms

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Aminoglycosides--50 years on

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Experience of once-daily aminoglycoside dosing using a target area under the concentration-time curve

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Monitoring of serum aminoglycoside levels with once-daily dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

A Bayesian feedback method of aminoglycoside dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Validation of the use of Bayesian analysis in the optimization of gentamicin therapy from the commencement of dosing

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Generation of pharmacokinetic data during routine therapeutic drug monitoring: Bayesian approach vs. pharmacokinetic studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Gentamicin levels in pregnant women with pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Prediction equation estimates of creatinine clearance in the intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900057-6

7 January 2021

10.1016/S0891-5520(03)00057-6

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14711074